Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share of Common Stock (Tables)

3 Months Ended

Mar. 31, 2023

The computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:

	2023			2022
	Three months ended March 31,
	2023			2022
Basic and diluted net loss per share:
Net loss available to common stockholders	$	(4,022,073	)	$	(3,227,131	)
Weighted average number of common shares-basic and diluted		22,770,789			15,831,118

Basic and diluted net loss per share	$	(0.18	)	$	(0.20	)